2Fujikawa Y, M Suzuki, H Iwasaki, et al. Quinoline type mevalonolactones [P]. EP 0 304 063,1989.
3Saito Y, M Kitahara, M Sakashita, et al. Inhibitor of atherosclerotic intimal thickening[ P]. US 6 162 798, 2000.
4Suzuki M, H Iwasaki, Y Fujikawa, et al. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors [ J ]. Bioorganic & Medicinal Chemistry,2001,9 (10) : 2727 - 2743.
5Ohara Y, M Suzuki, Y Yanagawa, et al. Diastereomer salt of optically active quinolinemevalonic acid[ P ]. US 5 284 953,1994.
6Suzuki M, Y Yanagawa, H Iwasaki, et al. First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104 [ J ]. Bioorganic & Medicinal Chemistry Letters,1999,9(20) :2977 -2982.
7Ohara Y, M Suzuki, Y Yanagawa, et al. Process for the preparation of quinoline derivative and intermediate therefor[ P]. US 6 335 449,2002.
8Karanewsky D S, M F Malley, J Z Gougoutas, et al. Practical synthesis of an enantiomerically pure synthon for the preparation of mevinic acid analogues[J]. J Org Chem, 1991,56:3744 - 3747.
9Rosen T, M Watanabe, C H Heathcock, et al. A convenient assay for the optical purity of monomethyl 3- hydroxypentanedioate[J]. J Org Chem,1984,49(19) : 3657 - 3659.
10ACEMOGLU, RISS. Process for the manufacture of HMG-CoA reductase inhibitors [P]. WO 2 003 064 392,2003.
8Ghandehari H, Kamal Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels inUS adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003 - 21)04[J]. Am Heart J,2008,156(1 ) : 112 -119.
9Moura FA, Saraiva F, Faria ED, et al. Seasonal variation of lipid profile and prevalence of dyslipidemia: A large population study[J]. J Am Coll Cardiol, 2013, 61(10) :E1330.
10Pinsky JL, Branch LG, Jette AM, et al. Framingham Disability Study: relationship of disability to cardiovascular risk factors among persons {ree of diagnosed cardiovascular disease[J]. Am J Epidemiol, 1985, 122(4):644-656.
